Teva Pharmaceutical Industries Limited Sees Unusually Large Options Volume (TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of some unusual options trading on Wednesday. Investors purchased 29,656 put options on the company. This represents an increase of 231% compared to the average volume of 8,957 put options.

Institutional investors have recently made changes to their positions in the company. San Francisco Sentry Investment Group CA purchased a new position in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $106,000. Kistler Tiffany Companies LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the period. FNY Managed Accounts LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 15.94 on Monday. The stock’s 50 day moving average price is $16.91 and its 200-day moving average price is $26.76. The stock’s market cap is $16.20 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.85.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.25 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.27 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.13%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.36%.

A number of equities research analysts recently issued reports on TEVA shares. Vetr upgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 price objective on the stock in a research note on Wednesday, June 28th. Royal Bank Of Canada restated an “outperform” rating and issued a $37.00 price objective (down from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, July 17th. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $21.00 price target (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, August 31st. Finally, BTIG Research upgraded Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday, September 11th. Five equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $27.63.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Limited Sees Unusually Large Options Volume (TEVA)” was originally published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-sees-unusually-large-options-volume-teva/1700382.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.